Seattle, WA (PRWEB) November 01, 2013
Quorum Review IRB, the industry leader in central IRB services, announces Regulatory Attorney J. Claire Carbary, JD, CIP, as a presenter at the 2013 PRIM&R Advancing Ethical Research Conference. The conference takes place November 7-9, in Boston, MA.
Ms. Carbary co-presents with J. Andy Bertolatus, Associate Professor of Internal Medicine at The University of Iowa, and Donna A. Messner, Research Director at Center for Medical Technology Policy. The presentation, Electronic Consent: A Discussion of the eConsent Experience, Ethical and Regulatory Considerations and the IRB Review Process, reviews the use of electronic consent using the iPad and computer-based interactive approaches. Presenters examine the regulatory requirements of IRB review and consent documentation and discuss the potential ethical challenges of using electronic technology in streamlining the informed consent process. The presentation takes place Saturday, November 9, at 11:15 AM in room 102.
J. Claire Carbary regularly delivers IRB-focused presentations covering such topics as: social media, HIPAA requirements and safety reporting. Ms. Carbary is a member of the Northwest Association for Biomedical Research and Public Responsibility in Medicine and Research. She received her Juris Doctor from Seattle University in 2007, and was admitted to the Washington State Bar Association (WSBA) in the fall of 2007.
PRIM&R’s annual Advancing Ethical Research Conference is an educational event for professionals working in the field of human subject protection. The conference brings together over 2,500 industry professionals from hospitals, universities, government, and other research institutions in an educational, three-day networking opportunity.
For the latest on Quorum Review News and Events, visit http://www.quorumreview.com.
About Quorum Review
Quorum Review is an independent institutional review board fully accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP), and has been providing IRB review of drug and device trials since 1992. Quorum oversees research in accordance with U.S. and Canadian human subject research protection regulations and guidelines set forth by the International Committee on Harmonisation (ICH), and principles of the Belmont Report.
Quorum’s best-in-class IRB services include 14 Board meetings each week plus expedited review, 24-hour site review turnaround, 36-hour amendment review turnaround, a secure web portal, and Smart Forms for online submissions. Quorum’s IRB service offerings include full study review in the US and Canada, a specialized Phase I team, and unique processes for post-approval and registry studies.